News and Press Releases
PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)
Phase 1b dataset with LYT-200 demonstrates complete responses and favorable tolerability across both R/R HR-MDS and R/R AML PureTech’s Founded Entity, Gallop Oncology, to advance LYT-200 first in R/R HR-MDS,...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 22, 2026
Lonza Launches Media Development Lab in Singapore for Cell Culture Media Optimisation
New media development services designed to optimize cell culture media development and identify robust, scalable media formulations driving cell culture performance and reliability The offering is designed to improve performance,...
Category: BioManufacturing, Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: March 26, 2026
ProteoNic 2G UNic Technology Licensed by Ginkgo Bioworks for BARDA-Supported Consortium Advancing Monoclonal Antibody Manufacturing for Anti-Filovirus Therapies
11 December 2025 -- Leiden, The Netherlands -- ProteoNic BV, a leading provider of premium vector technology for biopharmaceutical and viral vector production, today announced that its proprietary 2G UNic® technology...
Category: BioManufacturing, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 11, 2025
AGC Biologics Partners with ATUM to Accelerate Timelines for Cell Line Development
New offering provides drug developers with flexible and powerful cell line development options for monoclonal antibodies, multi-specific and complex molecules 2 December 2025 -- Washington State, US -- As drug developers face increasing pressure to lower...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: December 2, 2025
Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation
14 October 2025 -- New Jersey, US -- Tonix Pharmaceuticals Holding Corp, a fully integrated biotechnology company with marketed products and a pipeline of development candidates, today announced that Seth...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 14, 2025
Logical Biological and Bcell Design Announce Strategic Partnership for Engineered Disease State Materials
10 September 2025 -- Sandwich, UK and Illkirch-Graffenstaden, France -- Logical Biological, biospecimen and critical raw material leader, and Bcell Design, pioneers in transgenic monoclonal antibody technology, today announced a...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: October 10, 2025
Building 500, Discovery Park, Sandwich, Kent, CT13 9FE
Celltrion opens new UK headquarters in Uxbridge, UK
New office located in the heart of Uxbridge underscores Celltrion’s long-term business commitment in the UK 17 June 2025 -- London, UK -- Celltrion UK has officially opened its new...
Category: Clinical Trials, Drug Discovery, Manufacturing and Packing, Other, Pharmaceutical
Posted: June 17, 2025
Bionova Scientific Licenses ATUM’s Proprietary Transposon-Based Gene Delivery Technology to Accelerate & De-Risk Cell Line Development
7 May 2025 -- California, US and Düsseldorf, Germany -- Bionova Scientific, an Asahi Kasei boutique commercial-scale biologics contract development and manufacturing organization (CDMO), today announced it has licensed ATUM’s...
Category: Biotechnology, Drug Discovery, Manufacturing and Packing, Pharmaceutical
Posted: May 7, 2025
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
4 March 2025 -- New York, US -- Tiziana Life Sciences, Ltd, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 4, 2025
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom
Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter
25 February 2025 -- New York, US -- Tiziana Life Sciences, Ltd, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other
Posted: February 25, 2025
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom
Ellipses In-Licences First in Class Novel Immuno-Oncology Agent with Potential as a Next Generation Checkpoint Inhibitor
11 February 2025 -- London, UK -- Ellipses Pharma Limited, a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced...
Category: BioManufacturing, Drug Discovery, Other, Pharmaceutical
Posted: February 11, 2025
Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3
23 January 2025 -- New York, US -- Tiziana Life Sciences, Ltd, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: January 23, 2025
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab
17 December 2024 -- New York, US -- Tiziana Life Sciences, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: December 17, 2024
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom
PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting
LYT-200 is generally safe and well-tolerated as a single agent as well as in combination with standard-of-care venetoclax and hypomethylating agents LYT-200 demonstrates clinical benefit as a single agent, with...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: December 9, 2024
Sartorius Collaborates with Sanofi to Commercialise End-To-End Platform for Downstream Process Intensification
Sartorius selected as preferred partner for development and commercialisation of integrated and continuous biomanufacturing (ICB) platform Modular platform will combine highest flexibility with standardisation ICB supports lower resource consumption and...
Category: BioManufacturing, Pharmaceutical
Posted: May 13, 2024
Sartorius Corporation, Otto-Brenner-Straße 20, 37079 Goettingen, Germany
